Clinical Trial Update: A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia [Phase 2]

View source ↗

Summary

Phase II study of CPC-201 for Alzheimer's disease has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CPC-201

Snippet

Sponsor: Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-06-04